e-ISSN: Pending
WASTE Journal

Browse the failure-mode index

750 real negative results, null findings, and replication failures · Failed Experiment Report. Search the index →

WASTE indexes published research — it does not host or republish full papers. Each entry is a metadata record compiled from open scholarly databases; the abstract is shown in full only where the paper is openly licensed, otherwise a short excerpt under fair use. Classifications are automated and approximate.

Failed Experiment ReportMedicine

Population Genomics of <i>Macrophomina</i> spp. Reveals Cryptic Host Specialization and Evidence for Meiotic Recombination.

Pennerman KK, Goldman P, Dilla-Ermita CJ et al. · 2025 · Molecular plant-microbe interactions : MPMI

Knowledge of the factors structuring populations of pathogenic fungi is fundamental to disease management efforts and basic biology. However, this crucial information is missing for many important pathogens, including broad-host-range and…

View details →
Failed Experiment ReportOpen accessMedicine

Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Studies to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Relapsing and Progressive Forms of Multiple Sclerosis.

Cree BAC, Freedman MS, Gold M et al. · 2025 · Annals of neurology

Objective Elezanumab is a monoclonal antibody that binds repulsive guidance molecule a (RGMa), an inhibitor of central nervous system regeneration after inflammation or injury. The aim was to assess the safety and efficacy of elezanumab in…

View details →
Failed Experiment ReportMedicine

Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial.

Lee JM, Miller A, Rose PG et al. · 2025 · Clinical cancer research : an official journal of the American Association for Cancer Research

Purpose We assessed the efficacy of anti-PD-L1 durvalumab in combination with olaparib and cediranib (DOC), compared with the standard-of-care chemotherapy (SOC) in patients with platinum-resistant ovarian cancer (PROC), who had prior…

View details →
Failed Experiment ReportMedicine

Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer.

Andres S, Finch L, Iasonos A et al. · 2024 · Gynecologic oncology

Objective To determine the safety and efficacy of the oral progesterone antagonist onapristone extended release (onapristone-XR) in patients with recurrent progesterone receptor (PR)-positive adult-type granulosa cell tumor (aGCT),…

View details →
Failed Experiment ReportMedicine

A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis.

Ishikawa M, Shibata T, Iwata T et al. · 2021 · Gynecologic oncology

Objective To assess the efficacy and safety of dose-dense weekly paclitaxel plus carboplatin (ddTC) with or without bevacizumab compared to conventional, tri-weekly paclitaxel plus carboplatin (cTC) with or without bevacizumab, in…

View details →
Failed Experiment ReportOpen accessMedicine

Early identification of difficult-to-manage axial spondyloarthritis using machine-learning decision trees.

Juárez-García M, Plasencia-Rodríguez C, Benavent D et al. · 2026 · Therapeutic advances in musculoskeletal disease

Background Axial spondyloarthritis (axSpA) is an inflammatory disease in which, despite expanding therapeutic options, a substantial proportion of patients do not achieve the desired treatment target, highlighting the emerging concept of…

View details →
Failed Experiment ReportMedicine

Immunotherapy-Based Strategies for Treatment of Type 1 Diabetes.

Jacobsen LM, Schatz D · 2025 · Hormone research in paediatrics

Background Type 1 diabetes (T1D) is more than an insulin-deficiency disease - it is an autoimmune disease, and the field is moving toward adopting disease-modifying immunotherapy as part of clinical care during T1D development. Summary…

View details →
Failed Experiment ReportOpen accessMedicine

Antibiotic treatment of bacterial lung infections in cystic fibrosis.

Taccetti G, Terlizzi V, Campana S et al. · 2024 · European journal of pediatrics

Bacterial infections of the lower airways are the main cause of mortality and morbidity in cystic fibrosis. The most frequently isolated pathogens are S. aureus and P. aeruginosa; bacterial co-infections are frequently observed. The aim of…

View details →
Failed Experiment ReportOpen accessMedicine

Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial.

Mosca M, Arnaud L, Askanase A et al. · 2025 · Lupus science & medicine

Objective In PAISLEY, a 48-week, phase II, randomised controlled trial that assessed deucravacitinib in patients with active SLE, all primary and secondary endpoints were met with the deucravacitinib 3 mg two times per day dose. Changes in…

View details →
Failed Experiment ReportMedicine

Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306).

Pettengell R, Długosz-Danecka M, Andorsky D et al. · 2020 · British journal of haematology

PIX306 was a phase 3, randomised, single-blind, multicentre trial conducted in adult patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) grade 3 who relapsed after ≥1 rituximab-containing regimen and were not…

View details →
Failed Experiment ReportMedicine

A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer.

Tolaney SM, Sahebjam S, Le Rhun E et al. · 2020 · Clinical cancer research : an official journal of the American Association for Cancer Research

Purpose The primary objective was to evaluate intracranial objective response rate (iORR) in patients receiving abemaciclib with brain or leptomeningeal metastases (LM) secondary to hormone receptor-positive (HR + ) metastatic breast…

View details →
Failed Experiment ReportOpen accessMedicine

Tasting pain-relief through tongue stimulation: results from a feasibility study looking into the use of cranial nerve non-invasive neuromodulation in healthy individuals and chronic poststroke patients.

Ahiatsi M, Milot MH, Flaive A et al. · 2026 · BMC neurology

Purpose Chronic pain is a common consequence of stroke, often impairing survivors' quality of life. By targeting cranial nerves and brainstem regions involved in pain modulation, cranial nerve non-invasive neuromodulation (CN-NINM) offers…

View details →
Failed Experiment ReportOpen accessMedicine

Effects of early treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) on the bronchoalveolar lavage proteome and oxylipids during bovine respiratory syncytial virus (BRSV) infection.

Hägglund S, Laloy E, Alvarez I et al. · 2024 · PloS one

Non-steroidal anti-inflammatory drugs (NSAID) are not recommended for use against pneumonia in humans, but are commonly utilised against bovine respiratory disease. This study aimed to determine if the use of NSAIDs in the early phase of…

View details →
Failed Experiment ReportMedicine

Melatonin therapy reverses lead exposure-induced testicular damage in rats despite the lack of effect on serum testosterone levels.

Gallegos-Reyes MA, Antaño-Martínez AR, Alcaraz-Contreras Y et al. · 2023 · The Journal of toxicological sciences

Lead (Pb) exposure induces testicular damage and infertility. The aim of this study was to analyze and compare the therapeutic effects of antioxidants or vitamin D and calcium, which have previously been shown to reduce the toxic effects…

View details →
Failed Experiment ReportOpen accessMedicine

The Inflammatory Response in the Murine Ovalbumin-Induced Skin Inflammation Model Is Robust Despite Major Gut Microbiota Differences.

Henriksen IW, Bartholdy C, Koch J et al. · 2026 · Clinical and translational science

Valid pre-clinical animal models are essential for effective drug development in inflammatory skin diseases like atopic dermatitis. Most murine models exhibit low-to-moderate inflammatory responses with significant variability, undermining…

View details →
Failed Experiment ReportMedicine

Placebo-controlled three-armed pilot trial of Escitalopram or Nortriptyline for depressive symptoms in Parkinson's disease (ADepT-PD).

Schrag A, Embleton-Thirsk A, Carroll C et al. · 2026 · Journal of neural transmission (Vienna, Austria : 1996)

Pilot randomised-controlled trial of nortriptyline and escitalopram compared to placebo for depressive symptoms in people with Parkinson's disease (PD). Participants with PD and depressive symptoms received either nortriptyline,…

View details →